Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis
NCT ID: NCT01090310
Last Updated: 2016-01-14
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE3
86 participants
INTERVENTIONAL
2010-08-31
2011-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis
NCT01032915
Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis
NCT01095250
Extension Study to Assess Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis
NCT01103024
Safety and Efficacy of AIN457 in Noninfectious Uveitis
NCT00685399
Study to Evaluate the Long Term Use of Treatment With AIN457 for Uveitis
NCT01327664
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AIN457 300mg every 2 weeks
AIN457 300 mg subcutaneous (s.c.) weekly for 3 weeks followed by AIN457 300 mg s.c. every 2 weeks
AIN457
AIN457 150 mg powder for solution was provided in glass vials each containing 150 mg AIN457 as a lyophilized cake
AIN457 300 mg every 4 weeks
AIN457 300 mg s.c. at baseline for Week 2 followed by AIN457 300 mg s.c. monthly, alternating with placebo s.c. at Weeks 1 and 4 and then monthly
AIN457
AIN457 150 mg powder for solution was provided in glass vials each containing 150 mg AIN457 as a lyophilized cake
AIN457 150 mg every 4 weeks
AIN457 150 mg s.c. and placebo s.c. at Baseline and Week 2 followed by AIN457 150 mg s.c. monthly, alternating with placebo s.c. at Weeks 1 and 4 and then monthly
AIN457
AIN457 150 mg powder for solution was provided in glass vials each containing 150 mg AIN457 as a lyophilized cake
Placebo
Placebo s.c. every 2 weeks
Placebo
Matching placebo to AIN457
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AIN457
AIN457 150 mg powder for solution was provided in glass vials each containing 150 mg AIN457 as a lyophilized cake
Placebo
Matching placebo to AIN457
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novartis Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Novartis Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Novartis Investigative Site
Beverly Hills, California, United States
Novartis Investigative Site
Atlanta, Georgia, United States
Novartis Investigative Site
Louisville, Kentucky, United States
Novartis Investigative Site
Baltimore, Maryland, United States
Novartis Investigative Site
Cambridge, Massachusetts, United States
Novartis Investigative Site
Teaneck, New Jersey, United States
Novartis Investigative Site
Charlotte, North Carolina, United States
Novartis Investigative Site
Portland, Oregon, United States
Novartis Investigative Site
Arlington, Texas, United States
Novartis Investigative Site
Houston, Texas, United States
Novartis Investigative Site
São Paulo, São Paulo, Brazil
Novartis Investigative Site
São Paulo, São Paulo, Brazil
Novartis Investigative Site
Berlin, , Germany
Novartis Investigative Site
Kiel, , Germany
Novartis Investigative Site
Tübingen, , Germany
Novartis Investigative Site
New Delhi, , India
Novartis Investigative Site
Jerusalem, , Israel
Novartis Investigative Site
Petah Tikva, , Israel
Novartis Investigative Site
Ramat Gan, , Israel
Novartis Investigative Site
Tel Aviv, , Israel
Novartis Investigative Site
Barcelona, Catalonia, Spain
Novartis Investigative Site
Barcelona, Catalonia, Spain
Novartis Investigative Site
Santiago de Compostela, Galicia, Spain
Novartis Investigative Site
Madrid, Madrid, Spain
Novartis Investigative Site
Lausanne, CHE, Switzerland
Novartis Investigative Site
Lausanne, Switzerland, Switzerland
Novartis Investigative Site
Bern, , Switzerland
Novartis Investigative Site
Bern, , Switzerland
Novartis Investigative Site
Lucerne, , Switzerland
Novartis Investigative Site
Sankt Gallen, , Switzerland
Novartis Investigative Site
Zurich, , Switzerland
Novartis Investigative Site
Birmingham, , United Kingdom
Novartis Investigative Site
Liverpool, , United Kingdom
Novartis Investigative Site
London, , United Kingdom
Novartis Investigative Site
York, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2009-015508-24
Identifier Type: -
Identifier Source: secondary_id
CAIN457C2301E1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.